Gilead Sciences Revises Some of Its 2019 Guidance
July 30 2019 - 6:00PM
Dow Jones News
By Stephen Nakrosis
Gilead Sciences, Inc. (GILD) offered revised guidance for 2019
after the bell Tuesday.
The biopharmaceutical company said it was now expecting product
sales in a range between $21.6 billion and $22.1 billion for 2019,
above its previous range of $21.3 billion to $21.8 billion.
The new guidance reflects "favorable demand trends observed in
the first half of 2019 across Gilead's product portfolio," the
company said, including a greater impact from its generic version
of Letairis.
The company also said its "guidance for diluted EPS impact of
acquisition-related, up-front collaboration and licensing,
stock-based compensation and other expense was updated as a result
of the collaboration agreement with Galapagos NV." Gilead now sees
that number in a range between $3.90 and $4.00. It had previously
guided for a range of $1.40 to $1.50.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 30, 2019 17:45 ET (21:45 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024
